The discovery began, as many modern cancer biology investigations do, with proteomics. Rather than examining proteins one at a time, the researchers mapped the EphA2 interactome, the full constellation of proteins that physically associate with the EphA2 receptor, under conditions of progranulin stimulation. EphA2, or erythropoietin-producing hepatocellular carcinoma receptor A2, is a receptor tyrosine kinase that has long been implicated in cancer progression, but its behavior is unusual among kinase receptors: while it participates in normal developmental signaling, it is frequently overexpressed in aggressive tumors where its oncogenic function is driven less by classical kinase activity and more by its ability to recruit and organize signaling complexes. Progranulin, a secreted growth factor better known for its role in neurodegeneration, notably frontotemporal dementia, wound healing, and immune regulation, binds EphA2 and triggers downstream cascades. By comparing the composition of EphA2’s protein partners in the presence and absence of progranulin, the team uncovered a set of progranulin-dependent interactors, among them FAM120A, also known as Family with Sequence Similarity 120 Member A.

FAM120A is what biologists call a scaffold protein, a molecule that does not necessarily catalyze chemical reactions itself but instead serves as a physical platform upon which other signaling proteins assemble. This architectural role makes scaffold proteins powerful amplifiers and organizers of cellular communication, and disruptions in their function are increasingly recognized as contributors to malignancy. Using tissue microarrays and immunohistochemistry, the investigators demonstrated that FAM120A protein levels are elevated in bladder cancer tissues compared with normal tissue, suggesting that the protein is not merely a passive passenger but an active participant in the disease process.

To establish causality rather than mere correlation, the researchers turned to a battery of functional assays. They depleted FAM120A in bladder cancer cell lines using lentiviral shRNA approaches, a technique that uses viral vectors to deliver short hairpin RNA molecules capable of silencing a specific gene. The consequences were striking. Cells lacking FAM120A lost much of their clonogenic capacity, the ability to form colonies from single founder cells, a hallmark of cancer cell self-renewal. Wound healing assays, in which a scratch is made across a confluent cell monolayer and the rate of gap closure measured, showed dramatically impaired migratory capacity. Invasion through Matrigel, a synthetic basement membrane that mimics the extracellular matrix tumors must degrade to metastasize, was similarly crippled. Even three-dimensional spheroid formation, an in vitro model that captures aspects of tumor architecture more faithfully than flat cell culture, was compromised without FAM120A.

The team then extended these findings to anchorage-independent growth, assessed by soft agar assays, a classical test of malignant transformation in which cells must proliferate while suspended in semi-solid medium, something normal cells cannot do. FAM120A-depleted cells failed this test, and, critically, the loss of FAM120A also suppressed tumor formation in vivo using xenograft models, in which human cancer cells are implanted into immunocompromised mice. These animal experiments, performed under protocols approved by the Institutional Review Board of Thomas Jefferson University, provide the strongest evidence yet that FAM120A is not simply associated with aggressive bladder cancer but is functionally required for it.

Mechanistically, the study dissected how FAM120A exerts its oncogenic influence. Progranulin stimulation of bladder cancer cells is known to activate two major signaling highways: the AKT pathway, central to cell survival and growth, and the ERK1/2 pathway, a canonical mitogen-activated protein kinase cascade driving proliferation. Using western immunoblots, the researchers showed that FAM120A depletion blunted progranulin-evoked activation of both AKT and ERK1/2, placing the scaffold protein upstream of these critical signaling events. Co-immunoprecipitation experiments and proximity ligation assays, a technique that detects proteins located within roughly 40 nanometers of each other in intact cells, confirmed that the physical interaction between EphA2 and FAM120A is enhanced upon progranulin stimulation. Immunofluorescence microscopy further revealed colocalization of the two proteins within cells, painting a picture of a dynamically assembled signaling complex that assembles when progranulin arrives and drives the aggressive behavior of bladder cancer cells.

Perhaps the most mechanistically illuminating findings concern the cytoskeleton. For a cancer cell to migrate and invade, it must continuously remodel its actin cytoskeleton, the meshwork of F-actin filaments that provides mechanical force and shape. The team observed that progranulin stimulation triggers F-actin rearrangements in bladder cancer cells, and that this rearrangement is inhibited when FAM120A is depleted. Tracing the pathway further, they identified the small GTPase RhoA, a master regulator of actin dynamics and cell contractility, as a key mediator. Progranulin-induced activation of RhoA was abolished upon FAM120A depletion, and the researchers concluded that FAM120A operates through ERK1/2 and RhoA-dependent pathways to orchestrate the cytoskeletal changes that enable motility and invasion. This work builds on insights from experts in Rho protein biology, with the authors acknowledging discussions with Dr. Kenneth L. Van Golen of the University of Delaware.

The translational implications of these findings are twofold. First, FAM120A emerges as a candidate drug target. Because scaffold proteins occupy a nodal position in signaling networks, disrupting the EphA2-FAM120A interaction or destabilizing FAM120A itself could, in principle, simultaneously cripple multiple oncogenic outputs, from AKT-mediated survival to RhoA-driven invasion. Second, and more immediately achievable, FAM120A holds promise as a biomarker. Its upregulation in bladder cancer tissues suggests it could aid diagnosis, and the authors argue its expression patterns may carry prognostic value, potentially helping clinicians identify patients whose tumors are most likely to progress.

There is also an intriguing therapeutic synergy buried in the data. The researchers found that depleting FAM120A sensitized bladder cancer cells to cisplatin, a cornerstone chemotherapy drug used in the treatment of muscle-invasive and metastatic bladder cancer. Cisplatin kills cells primarily by cross-linking DNA, but resistance is a persistent clinical problem. The observation that removing a scaffold protein from a growth factor signaling axis can restore chemosensitivity hints that combinations of standard chemotherapy with agents targeting the progranulin/EphA2/FAM120A circuitry could one day improve outcomes, though such strategies remain firmly in the preclinical realm.

The collaborative nature of the study reflects the complexity of the problem. The work united researchers from Temple University in Philadelphia, Thomas Jefferson University’s Sidney Kimmel Cancer Center, the University of Siena, the University of Milano-Bicocca, the University of Naples Federico II, the University of Catania, the Mayo Clinic Alix School of Medicine, and the S.H.R.O. Italia Foundation, with funding from the Sbarro Health Research Organization and National Institutes of Health grants supporting Thomas Jefferson University’s Translational Core Facility. Corresponding author Andrea Morrione and colleagues, including co-author Antonio Giordano, director of the Sbarro Institute, and veteran extracellular matrix researcher Renato V. Iozzo, brought complementary expertise in growth factor signaling, proteomics, tumor biology, and translational oncology to bear on the question.

Important caveats remain. The study relies heavily on cell lines and xenograft models, which, while informative, do not fully recapitulate the heterogeneity of human bladder tumors or the microenvironment in which they grow. Whether FAM120A expression levels correlate with patient outcomes in large clinical cohorts, whether the protein can be safely and effectively targeted pharmacologically, and how its function intersects with established bladder cancer drivers such as FGFR3 alterations and immune checkpoint pathways are questions that will require substantial further research. The fact that progranulin also participates in neurodegenerative disease adds another layer of complexity, as any therapeutic strategy modulating progranulin signaling must carefully consider effects beyond the tumor.

Nevertheless, the identification of FAM120A as an oncogenic effector in the progranulin/EphA2 axis represents a meaningful advance in understanding how bladder cancer cells acquire their invasive, treatment-resistant phenotype. By converting a proteomic observation into a mechanistic model validated across molecular, cellular, and animal levels, the study provides the scientific community with both a new lens on an established signaling pathway and a concrete starting point for the development of diagnostic markers and therapeutic interventions. For a disease that kills nearly 18,000 Americans each year, that is progress worth noting.

The challenge of chemoresistance remains a critical obstacle in effective cancer management. Cisplatin, while potent, often loses efficacy in a subset of bladder cancer patients due to genetic and cellular alterations that confer drug resistance. One such genetic factor is the deficiency of MSH2, a key protein involved in the DNA mismatch repair (MMR) system. Loss of MSH2 function disrupts DNA repair mechanisms, leading to genomic instability and ultimately fostering a tumor microenvironment less responsive to cisplatin-induced DNA damage.

TGM2, a multifunctional enzyme known for its role in post-translational modification of proteins, has increasingly drawn attention for its involvement in cancer progression and drug resistance. The enzyme catalyzes the crosslinking of proteins and has been implicated in processes such as apoptosis, cell adhesion, and extracellular matrix stabilization. Yet, its precise role in modulating chemotherapy response in MSH2-deficient tumors remained poorly understood until now.

In the detailed experimental design presented by Wei et al., bladder cancer cell lines deficient in MSH2 were treated with a TGM2 inhibitor alongside cisplatin. The findings revealed a striking increase in cisplatin sensitivity upon TGM2 inhibition, suggesting that TGM2 acts as a protective factor allowing cancer cells to withstand cisplatin’s cytotoxic effects. This synergy between TGM2 inhibition and cisplatin exposure was demonstrated through multiple assays that measured cell viability, apoptosis rates, and DNA damage markers.

Mechanistically, the study sheds light on the interplay between TGM2 and the DNA damage response (DDR) pathways. By inhibiting TGM2, cancer cells exhibited heightened DNA damage accumulation following cisplatin treatment, implying a compromised ability to repair cisplatin-induced lesions. This is particularly relevant in MSH2-deficient cells, which already have impaired MMR pathways, making them more reliant on alternative repair mechanisms that may be facilitated by TGM2. Thus, TGM2 inhibition likely disrupts these compensatory pathways, amplifying cisplatin’s therapeutic impact.

The implications of these findings extend beyond laboratory observations. Current clinical protocols for bladder cancer often fail to consider the genetic heterogeneity of tumors, which can significantly influence treatment outcomes. Wei and colleagues propose that TGM2 inhibitors could be developed as adjuvant therapies to specifically target MSH2-deficient bladder cancers. Incorporating such inhibitors could sensitize tumors to cisplatin, potentially reducing the necessary dosage and mitigating side effects while overcoming resistance.

Additionally, this research highlights the importance of genetic screening in the clinical setting. Determining MSH2 status in bladder cancer patients could become a routine practice that guides the use of TGM2-targeted therapies. This personalized medicine approach aligns with contemporary trends in oncology, aiming to tailor treatments based on individual tumor profiles to maximize efficacy and minimize toxicity.

The study also prompts deeper considerations into how TGM2 modulates cellular pathways beyond protein crosslinking. The enzyme’s involvement in apoptosis regulation suggests that its inhibition might restore programmed cell death mechanisms impaired in resistant cancer cells. This dual action—enhancing DNA damage and promoting apoptosis—could explain the robust increase in cisplatin sensitivity, positioning TGM2 as a multifaceted therapeutic target.

Future research directions outlined by the authors include in vivo validation of TGM2 inhibitors in animal models of MSH2-deficient bladder cancer. Such studies will be pivotal in assessing the pharmacodynamics, optimal dosing regimens, and potential off-target effects of these inhibitors. Moreover, expanding this research to other cancer types characterized by MSH2 deficiency may broaden the clinical applicability of TGM2 inhibition strategies.

The molecular intricacies unraveled in this study also emphasize the evolving understanding of cancer as a disease driven by complex genetic and proteomic networks. Targeting key nodes like TGM2 in these networks offers a promising strategy for dismantling the robust defenses of chemoresistant tumors. This approach exemplifies the shift from non-specific cytotoxic agents to precision oncology, where treatments are fine-tuned to exploit particular vulnerabilities within cancer cells.

Collateral benefits of TGM2 inhibition may include modulating the tumor microenvironment, given the enzyme’s role in extracellular matrix remodeling. Disrupting these structural components might further enhance the penetration and efficacy of chemotherapeutic drugs like cisplatin, adding another layer to potential therapeutic mechanisms.

Clinically, incorporating TGM2 inhibitors could revolutionize treatment protocols for bladder cancer, a malignancy with substantial morbidity and mortality worldwide. While cisplatin remains a cornerstone drug, the prospect of combining it with targeted agents to surmount resistance is a compelling advancement. This strategy could improve survival rates and quality of life for patients facing otherwise refractory disease.

A notable facet of this research is the sophisticated use of molecular biology techniques, including gene knockdown and CRISPR-mediated gene editing, which allowed precise modeling of MSH2 deficiency in cell lines. This precision enabled the authors to draw firm conclusions about the causative role of TGM2 in mediating drug response, reinforcing the robustness of their findings.

Together, these insights pave the way for clinical trials that could integrate TGM2 inhibitors into standard chemotherapeutic regimens. The promise of translating molecular discoveries into tangible patient benefits embodies the ultimate goal of cancer research, evoking cautious optimism among clinicians and patients alike.

Wei, Xiao, Ren, and their team’s contribution stands as a testament to the power of targeted molecular interventions in redefining the therapeutic landscape. As these findings gain traction, they may spark a wave of innovation in the development of companion diagnostics and novel drug formulations aimed at combating chemoresistance.

In essence, the inhibition of TGM2 in MSH2-deficient bladder cancer cells represents a beacon of hope, illuminating a path toward more effective, tailored chemotherapy options. This advancement underscores the dynamic interplay between genetic defects and enzymatic activity in shaping cancer behavior, reminding us that unlocking cancer’s vulnerabilities often requires peeling back the layers of its intricate molecular machinery.

Subject of Research: Enhancement of cisplatin sensitivity in MSH2-deficient bladder cancer through TGM2 inhibition.

Article Title: Inhibition of TGM2 enhances cisplatin sensitivity in MSH2-deficient bladder cancer.

Article References:
Wei, W., Xiao, X., Ren, C. et al. Inhibition of TGM2 enhances cisplatin sensitivity in MSH2-deficient bladder cancer. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03182-z

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-026-03182-z